surging news feed (www.thepaper.cn) from human medicinal drug safety administration center website inquiry found that the drug firms bristol-myers squibb (BMS), PD – 1 single Opdivo resistance (Chinese name worth of single resistance) have been filing, human medicinal center has been accepted.
data diagram (for figure/visual China)
Opdivo prove to be the first in China filing/PD PD – 1 – L1 drugs. As of November 4, the drug is still in the listing application queue pending state. Accelerating in food administration of drug safety review of new drugs listed a series of reform background, Opdivo could quickly through public examination and approval.
surging news understands, by the food drug administration (FDA) approved Opdivo indications, including melanoma, non-small cell lung cancer, head and neck cancer, renal cell carcinoma, non-hodgkin’s lymphoma, typical urothelial carcinoma, colorectal cancer, stomach cancer, can also be used in the treatment of always treated with sorafenib treatment of patients with hepatocellular carcinoma (HCC).
after some anti-cancer drugs, including Opdivo, failed to list at home, the mainland part of the cancer patients have to choose transnational treatment or buy medicine.
Hong Kong comprehensive cancer center director of surgery specialist Pan Dongping previously said in an interview with the media on the mainland, because Hong Kong is the standard drug reference American FDA approval, so many new drugs can be used in Hong Kong, but it is still in the drug safety administration of the approval process. In general, listed in Hong Kong, new drugs to 5 to 7 years earlier than the mainland, like immunotherapy drugs, expects the mainland to 2022 can be listed. In immunotherapy this piece, therefore, the center also exploded many from the mainland to Hong Kong for treatment of patients.